Another NK-1R antagonist, serlopitant, was tested for the treatment of pruritus associated with prurigo nodularis (phase 2 trial positive, phase 3 negative), pruritus associated with psoriasis (phase 2 trial positive), CPUO (phase 2 trial positive), and pruritus associated with epidermolysis bullosa (phase 2 trial negative) [156–160]. Here, TACR1 is linked to Pruritus.